UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 21, 2013
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
(State or other jurisdiction of Incorporation) |
|
0-50440 |
|
20-2590184 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
1550 East Gude Drive, Rockville MD |
|
20850 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On November 21, 2013, Supernus issued a press release announcing that the company’s management will present an overview of the Company at an investor conference on December 4, 2013, a copy of which is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits
|
(d) |
Exhibits |
|
|
The following document is furnished as an Exhibit pursuant to Item 8.01 hereof: |
|
|
Exhibit 99.1 – Press Release dated November 21, 2013. |
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
SUPERNUS PHARMACEUTICALS, INC. |
|
|
|
|
DATED: November 21, 2013 |
By: /s/ Gregory S. Patrick |
|
|
Gregory S. Patrick |
|
|
Vice-President and Chief Financial Officer |
|
|
|
EXHIBIT INDEX
|
Number |
Description |
|
|
|
|
|
|
99.1 |
Press Release dated November 21, 2013. |
Attached |
|
|
|
|
|
|
|
|
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
Supernus to Present at Piper Jaffray Healthcare Conference in December
Rockville, MD, November 21, 2013 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will present an overview of the Company at the Piper Jaffray Healthcare Investor Conference.
Presentation Date: Wednesday, December 4
Time: 3:00pm ET
Place: The New York Palace, New York, NY
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XRTM (extended release oxcarbazepine), and Trokendi XRTM (extended release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591